• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[眼表的抗血管生成治疗:时机、方法及原因?]

[Antiangiogenic therapy at the ocular surface: when, what and why?].

作者信息

Bock F, Regenfuss B, Cursiefen C

机构信息

Augenklinik mit Poliklinik, Labor für Okuläre Angiogenese, Lymphangiogenese und Transplantatimmunologie, Universität Erlangen-Nürnberg, Universitäts-Augenklinik Erlangen, Schwabachanlage 6, 91054, Erlangen, Deutschland.

出版信息

Ophthalmologe. 2011 Mar;108(3):230-6. doi: 10.1007/s00347-010-2262-0.

DOI:10.1007/s00347-010-2262-0
PMID:21271256
Abstract

There are numerous indications for local antiangiogenic therapy at the ocular surface. These include vision-limiting corneal neovascularization, corneal blood and lymphatic vessels endangering corneal graft survival and tumor-associated lymphangiogenesis. A literature review in PubMed and own clinical and experimental data form the basis for a discussion of the indications, current therapeutic options and potential side-effects of local antiangiogenic therapy at the ocular surface.

摘要

眼表局部抗血管生成治疗有多种适应证。这些适应证包括限制视力的角膜新生血管形成、危及角膜移植存活的角膜血管和淋巴管以及肿瘤相关的淋巴管生成。对PubMed的文献综述以及自身的临床和实验数据构成了讨论眼表局部抗血管生成治疗的适应证、当前治疗选择和潜在副作用的基础。

相似文献

1
[Antiangiogenic therapy at the ocular surface: when, what and why?].[眼表的抗血管生成治疗:时机、方法及原因?]
Ophthalmologe. 2011 Mar;108(3):230-6. doi: 10.1007/s00347-010-2262-0.
2
Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases.新型抗(淋巴)血管生成治疗策略在角膜和眼表疾病中的应用。
Prog Retin Eye Res. 2013 May;34:89-124. doi: 10.1016/j.preteyeres.2013.01.001. Epub 2013 Jan 22.
3
[Anti(lymph)angiogenic preconditioning prior to keratoplasty].角膜移植术前的抗(淋巴)血管生成预处理
Klin Monbl Augenheilkd. 2013 May;230(5):500-4. doi: 10.1055/s-0032-1328500. Epub 2013 May 21.
4
Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty.周边巩膜bevacizumab 注射治疗深层板层角膜移植术后眼前段界面新生血管。
Cornea. 2010 Nov;29(11):1268-72. doi: 10.1097/ICO.0b013e3181d92834.
5
[Angiogenesis and lymphangiogenesis in the cornea. Pathogenesis, clinical implications and treatment options].[角膜中的血管生成与淋巴管生成。发病机制、临床意义及治疗选择]
Ophthalmologe. 2003 Apr;100(4):292-9. doi: 10.1007/s00347-003-0798-y.
6
Photodynamic Therapy Leads to Time-Dependent Regression of Pathologic Corneal (Lymph) Angiogenesis and Promotes High-Risk Corneal Allograft Survival.光动力疗法可导致病理性角膜(淋巴)血管生成随时间推移而消退,并促进高危角膜移植存活。
Invest Ophthalmol Vis Sci. 2017 Nov 1;58(13):5862-5869. doi: 10.1167/iovs.17-22904.
7
Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.结膜下注射贝伐单抗治疗复发性翼状胬肉角膜新生血管化
Curr Eye Res. 2008 Jan;33(1):23-8. doi: 10.1080/02713680701799101.
8
Treatment of inflamed pterygia or residual pterygial bed.治疗发炎的翼状胬肉或残留的翼状胬肉床。
Br J Ophthalmol. 2009 Jul;93(7):864-5. doi: 10.1136/bjo.2008.155291.
9
Pterygia: pathogenesis and the role of subconjunctival bevacizumab in treatment.翼状胬肉:发病机制及结膜下贝伐单抗在治疗中的作用
Semin Ophthalmol. 2009 May-Jun;24(3):130-4. doi: 10.1080/08820530902801106.
10
Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study.阿加尼尔森反义寡核苷酸滴眼液抑制角膜炎诱导的角膜新生血管形成,减少移植需求:I-CAN 研究。
Ophthalmology. 2014 Sep;121(9):1683-92. doi: 10.1016/j.ophtha.2014.03.038. Epub 2014 May 6.

引用本文的文献

1
[Pterygium: what about point of care biomarkers?].[翼状胬肉:即时检验生物标志物如何?]
Ophthalmologe. 2021 Jul;118(7):765-766. doi: 10.1007/s00347-021-01414-4. Epub 2021 May 31.
2
Emerging techniques to treat corneal neovascularisation.新兴技术治疗角膜新生血管。
Eye (Lond). 2012 Jan;26(1):2-12. doi: 10.1038/eye.2011.246. Epub 2011 Oct 7.

本文引用的文献

1
Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis.角膜新生血管是角膜移植术后移植物失败和排斥的危险因素:一项基于证据的荟萃分析。
Ophthalmology. 2010 Jul;117(7):1300-5.e7. doi: 10.1016/j.ophtha.2010.01.039. Epub 2010 Jun 3.
2
Anti-VEGF therapy for glaucoma.抗血管内皮生长因子治疗青光眼。
Curr Opin Ophthalmol. 2010 Mar;21(2):112-7. doi: 10.1097/ICU.0b013e3283360aad.
3
Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation.
前沿:淋巴管而非血管,在移植后主要介导免疫排斥。
J Immunol. 2010 Jan 15;184(2):535-9. doi: 10.4049/jimmunol.0903180. Epub 2009 Dec 16.
4
Intraocular tumor-associated lymphangiogenesis a novel prognostic factor for ciliary body melanomas with extraocular extension?眼内肿瘤相关淋巴管生成:睫状体黑色素瘤眼外侵犯的新预后因素?
Ophthalmology. 2010 Feb;117(2):334-42. doi: 10.1016/j.ophtha.2009.06.057. Epub 2009 Nov 4.
5
Cellular-level characterization of lymph vessels in live, unlabeled corneas by in vivo confocal microscopy.利用活体共聚焦显微镜对活体、未经标记的角膜中的淋巴管进行细胞水平的特征描述。
Invest Ophthalmol Vis Sci. 2010 Feb;51(2):830-5. doi: 10.1167/iovs.09-4407. Epub 2009 Sep 24.
6
GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial.GS-101反义寡核苷酸滴眼液可抑制角膜新生血管形成:一项随机II期试验的中期结果
Ophthalmology. 2009 Sep;116(9):1630-7. doi: 10.1016/j.ophtha.2009.04.016. Epub 2009 Jul 29.
7
Tumour-associated lymphangiogenesis in conjunctival malignant melanoma.结膜恶性黑色素瘤中的肿瘤相关淋巴管生成
Br J Ophthalmol. 2009 Nov;93(11):1529-34. doi: 10.1136/bjo.2008.147355. Epub 2009 Jul 23.
8
[Antiangiogenic therapy for pterygium recurrence].[翼状胬肉复发的抗血管生成治疗]
Ophthalmologe. 2009 May;106(5):413-9. doi: 10.1007/s00347-009-1936-y.
9
Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.局部应用贝伐单抗(阿瓦斯汀)滴眼液治疗角膜新生血管的短期和长期安全性及疗效
Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1375-82. doi: 10.1007/s00417-009-1099-1. Epub 2009 May 5.
10
Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation.术后短暂性血管内皮生长因子(VEGF)中和可提高伴有部分消退性炎性新生血管的角膜移植存活率。
Br J Ophthalmol. 2009 Aug;93(8):1075-80. doi: 10.1136/bjo.2008.145128. Epub 2009 Feb 17.